Cosmax (A192820) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
20 Feb, 2026Executive summary
Consolidated sales reached 551.5 KRW bn, up 15.1% year-over-year, with Korea leading growth and Southeast Asia outperforming guidance.
Operating profit rose 1.5% YoY to 46.7 KRW bn, while net income increased 28.9% YoY to 35.3 KRW bn.
Korea saw robust export and domestic sales, while China faced weak consumer sentiment and the US normalized after a strong prior year.
Financial highlights
Gross profit increased 35.0% YoY to 112.0 KRW bn, with a stable cost ratio at 79.7%.
SG&A expenses rose 76.8% YoY, impacting operating leverage.
Non-operating profit of 5 KRW bn and corporate income tax of 16.4 KRW bn were recorded.
Outlook and guidance
Southeast Asia exceeded annual guidance, driven by strong category growth and favorable business conditions.
Latest events from Cosmax
- Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.A192820
Q3 202420 Feb 2026 - Record Q4 profit growth driven by Korea and Southeast Asia, with net profit turning positive.A192820
Q4 202420 Feb 2026 - Revenue and operating profit grew, but net profit dropped due to one-off and non-operating losses.A192820
Q1 202520 Feb 2026 - Revenue up 1.0% YoY, but net loss widened on one-off costs; BTI outperformed.A192820
Q3 202520 Feb 2026 - Record revenue and profit growth offset by net profit decline from non-operating expenses.A192820
Q2 202512 Aug 2025